Newron's Two-Stage Drama: A Patent Win in Germany Buys Time as Evenamide Faces FDA Scrutiny

Biotech investors following Newron are juggling two very different narratives. One involves a decisive legal victory for the company's existing Parkinson's drug in its most important market. The other concerns the FDA speed bump that has added uncertainty to the pivotal schizophrenia programme expected to define the stock's trajectory.

On the Xadago front, the Munich Regional Court has granted preliminary injunctions against three generic-drug makers — Vivanta Generics, Stadapharm, and Aliud Pharma — barring them from selling copycat versions of safinamide in Germany. The decision came without a trial and rests on a supplementary protection certificate issued by Germany's Federal Patent Court, which shields Xadago from April 2024 through April 2029. The orders were handed down even as the generics had already entered the German market.

Vivanta has challenged the injunctions, and a hearing is set for July 2026. No nullity actions have been filed yet against the German SPC, though market watchers consider them a likely next step given that similar certificates have already been invalidated in Sweden, Belgium, Spain, and the UK — appeals are pending in those jurisdictions. In the Netherlands, Newron won a different battle in January 2026, securing a sales ban and a recall of Vivanta's generics.

The German success matters because the country accounts for the lion's share of Xadago's European commercial value. The drug generated €7.8 million in licence income from partner Zambon in 2025, up from €6.9 million the year before. Those royalties help fund the broader research effort, including development of the company's pipeline candidate Evenamide.

Should investors sell immediately? Or is it worth buying Newron SpA?

That neuroscience asset is now at the centre of investor attention — and a fresh regulatory headwind. In late April, the FDA halted enrolment of new patients at US sites for ENIGMA-TRS 2, the second of two phase III trials testing Evenamide in treatment-resistant schizophrenia. The stop was triggered by the sudden death of a study participant at a site outside the US. The investigator judged the event not related to treatment, and an independent safety board later recommended the study continue as planned.

The pause applies only to US centres. Recruiting continues in Argentina and India, where regulatory clearances have been granted, and is nearing the final stages in Colombia and Malaysia. A separate phase III study, ENIGMA-TRS 1, which targets at least 600 patients across 21 countries, remains fully active and has already enrolled more than 400 patients.

Newron's management is aiming to put the FDA episode into context during two upcoming investor conferences. CEO Stefan Weber and CFO Roberto Galli will present at the Jefferies Global Healthcare Conference in New York on 4 June, followed by a virtual appearance at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on 15-16 June. The presentations come at a fragile moment for the shares: after closing at €15.80, the stock has shed over 40% since the start of the year, despite a 12% rebound over the past month.

The FDA snag has done little to alter the timeline for the most critical catalyst. Newron still expects to release the 12-week primary endpoint data from the Evenamide programme in the fourth quarter of 2026. That readout will determine whether the drug's glutamatergic mechanism can deliver durable symptom improvements in a difficult patient population. Early-phase studies have shown increasing and sustained benefit, but the phase III results are the ultimate proof.

Funding for the run-up to those data appears secure. In February 2026, Newron arranged a share placement worth up to €38 million from European and Asian investors. A month later, the company renegotiated the terms of its 2018 financing agreement with the European Investment Bank, extending the maturity of all outstanding tranches to June 2028.

Newron SpA at a turning point? This analysis reveals what investors need to know now.

Evenamide's Japanese prospects add an extra dimension. Partner EA Pharma, part of the Eisai group, began its own phase III trial in Japan in January 2026, holding rights to develop, manufacture, and market the compound there and in selected other Asian markets.

Back in Germany, the Xadago litigation is far from over. The July hearing with Vivanta will test whether the preliminary injunctions are converted into permanent orders. But for now, the court decision provides breathing room — and a stream of royalties that keeps Newron's research engine running while the market waits for Evenamide's make-or-break moment.

Ad

Newron SpA Stock: New Analysis - 29 May

Fresh Newron SpA information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Newron SpA analysis...

en | IT0004147952 | NEWRONS | boerse | 69443256 |